+

WO2009081368A3 - Cosmetic use desmoglein i-type proteins - Google Patents

Cosmetic use desmoglein i-type proteins Download PDF

Info

Publication number
WO2009081368A3
WO2009081368A3 PCT/IB2008/055459 IB2008055459W WO2009081368A3 WO 2009081368 A3 WO2009081368 A3 WO 2009081368A3 IB 2008055459 W IB2008055459 W IB 2008055459W WO 2009081368 A3 WO2009081368 A3 WO 2009081368A3
Authority
WO
WIPO (PCT)
Prior art keywords
desmoglein
polypeptide
cosmetic use
type proteins
analogues
Prior art date
Application number
PCT/IB2008/055459
Other languages
French (fr)
Other versions
WO2009081368A2 (en
Inventor
Dominique Bernard
Lucie Simonetti
Isabelle Castiel
Original Assignee
L'oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L'oreal filed Critical L'oreal
Publication of WO2009081368A2 publication Critical patent/WO2009081368A2/en
Publication of WO2009081368A3 publication Critical patent/WO2009081368A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The subject of the present invention is the use, in particular cosmetic and/or therapeutic use, of desmoglein I, of polypeptides derived from this protein or of analogues thereof, of a nucleic sequence encoding such a polypeptide or of an agent for modulating the activity, the stability or the expression of such a polypeptide, in particular for preventing and/or treating the signs of skin aging. The invention also relates to the use of desmoglein I, of polypeptides derived from this protein or analogues thereof, or of a nucleic sequence encoding such a polypeptide, as a marker for evaluating a state of an epithelium.
PCT/IB2008/055459 2007-12-19 2008-12-19 Cosmetic use desmoglein i-type proteins WO2009081368A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0759992 2007-12-19
FR0759992A FR2925312B1 (en) 2007-12-19 2007-12-19 COSMETIC USE OF DESMOGLEINE I PROTEINS
US2061708P 2008-01-11 2008-01-11
US61/020,617 2008-01-11

Publications (2)

Publication Number Publication Date
WO2009081368A2 WO2009081368A2 (en) 2009-07-02
WO2009081368A3 true WO2009081368A3 (en) 2010-04-29

Family

ID=39847073

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/055459 WO2009081368A2 (en) 2007-12-19 2008-12-19 Cosmetic use desmoglein i-type proteins

Country Status (2)

Country Link
FR (1) FR2925312B1 (en)
WO (1) WO2009081368A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2940976B1 (en) 2009-01-13 2017-11-03 Oreal USE FOR THE SCREENING OF ANTI-AGES ACTIVE INGREDIENTS OF SOLUBLE FORMS OF THE DESMOGLEINE I PROTEIN
GB2473432A (en) * 2009-09-09 2011-03-16 Anton Alexandroff Improvements in or relating to exfoliation
US9750674B2 (en) 2010-06-11 2017-09-05 The Procter & Gamble Company Compositions for treating skin
US9671410B2 (en) 2011-01-16 2017-06-06 The Procter & Gamble Company Biomarker-based methods for identifying and formulating compositions that improve skin quality and reduce the visible signs of aging in skin
EP3217948B1 (en) 2014-11-10 2020-09-16 The Procter and Gamble Company Personal care compositions with two benefit phases
US10085924B2 (en) 2014-11-10 2018-10-02 The Procter & Gamble Company Personal care compositions
CN107106474B (en) 2014-11-10 2021-06-01 宝洁公司 Personal care composition with two benefit phases
US10966916B2 (en) 2014-11-10 2021-04-06 The Procter And Gamble Company Personal care compositions
WO2017182609A1 (en) * 2016-04-22 2017-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of inflammatory skin diseases associated with desmoglein-1 deficiency
CN111212625B (en) 2017-10-20 2023-05-23 宝洁公司 Aerosol foam skin cleaner
WO2019079405A1 (en) 2017-10-20 2019-04-25 The Procter & Gamble Company Aerosol foam skin cleanser
WO2019113035A1 (en) 2017-12-08 2019-06-13 The Procter & Gamble Company Methods of screening for mild skin cleanser
GB201819345D0 (en) 2018-11-28 2019-01-09 X Biocell Ltd Improvemets in or reating to biological exfoliation
CN113015904B (en) 2018-11-29 2024-06-18 宝洁公司 Method for screening personal care products

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000651A1 (en) * 1993-06-18 1995-01-05 Astra Aktiebolag Recombinant stratum corneum chymotryptic enzyme (scce)
JPH08337537A (en) * 1995-06-15 1996-12-24 Kao Corp Intercellular adhesion inhibiting peptide
EP1075835A1 (en) * 1999-08-09 2001-02-14 Shiseido Company Limited Use of aminodiol derivatives in skin cosmeics
JP2001288113A (en) * 2000-04-05 2001-10-16 Lion Corp Skin care composition
US20040142335A1 (en) * 2001-01-03 2004-07-22 Dirk Petersohn Method for determining skin stress or skin ageing in vitro
US20050191709A1 (en) * 2004-02-26 2005-09-01 The Procter & Gamble Company Methods for determining the relative benefits and/or evaluating quantitative changes of products on epithelial tissue
US20050203025A1 (en) * 1998-05-05 2005-09-15 Adherex Technologies, Inc. Compounds and methods for modulating nonclassical cadherin-mediated functions
JP2006008570A (en) * 2004-06-24 2006-01-12 Club Cosmetics Co Ltd Epidermolytic toxin inhibitor and external preparation for the skin using the same
JP2007199053A (en) * 2005-12-28 2007-08-09 Kose Corp Horny layer protein detecting method and methods for evaluating epidermis turnover and skin state using same

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000651A1 (en) * 1993-06-18 1995-01-05 Astra Aktiebolag Recombinant stratum corneum chymotryptic enzyme (scce)
JPH08337537A (en) * 1995-06-15 1996-12-24 Kao Corp Intercellular adhesion inhibiting peptide
US20050203025A1 (en) * 1998-05-05 2005-09-15 Adherex Technologies, Inc. Compounds and methods for modulating nonclassical cadherin-mediated functions
EP1075835A1 (en) * 1999-08-09 2001-02-14 Shiseido Company Limited Use of aminodiol derivatives in skin cosmeics
JP2001288113A (en) * 2000-04-05 2001-10-16 Lion Corp Skin care composition
US20040142335A1 (en) * 2001-01-03 2004-07-22 Dirk Petersohn Method for determining skin stress or skin ageing in vitro
US20050191709A1 (en) * 2004-02-26 2005-09-01 The Procter & Gamble Company Methods for determining the relative benefits and/or evaluating quantitative changes of products on epithelial tissue
JP2006008570A (en) * 2004-06-24 2006-01-12 Club Cosmetics Co Ltd Epidermolytic toxin inhibitor and external preparation for the skin using the same
JP2007199053A (en) * 2005-12-28 2007-08-09 Kose Corp Horny layer protein detecting method and methods for evaluating epidermis turnover and skin state using same

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BARTOLONE J ET AL: "A NON-INVASIVE APPROACH FOR ASSESSING CORNEOCYTE COHESION IMMUNOCHEMICAL DETECTION OF DESMOGLEIN I", CLINICAL RESEARCH, THOROFARE, NJ, US, vol. 39, no. 2, 1 January 1991 (1991-01-01), pages 471A, XP009105453, ISSN: 0009-9279 *
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; August 2006 (2006-08-01), HARATAKE A ET AL: "Acceleration of de novo cholesterol synthesis in the epidermis influences desquamation of the stratum corneum in aged mice", XP002501140, Database accession no. EMB-2006428982 *
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; November 2004 (2004-11-01), HATAKEYAMA S ET AL: "Retinoic acid disintegrated desmosomes and hemidesmosomes in stratified oral keratinocytes", XP002501139, Database accession no. EMB-2004479916 *
DATABASE WPI Week 200608, Derwent World Patents Index; AN 2006-073497, XP002501141 *
JOURNAL OF ORAL PATHOLOGY AND MEDICINE 200411 GB, vol. 33, no. 10, November 2004 (2004-11-01), pages 622 - 628, XP002501137, ISSN: 0904-2512 *
SKIN PHARMACOLOGY AND PHYSIOLOGY 200608 CH, vol. 19, no. 5, August 2006 (2006-08-01), pages 275 - 282, XP002501138, ISSN: 1660-5527 *

Also Published As

Publication number Publication date
FR2925312B1 (en) 2016-12-02
WO2009081368A2 (en) 2009-07-02
FR2925312A1 (en) 2009-06-26

Similar Documents

Publication Publication Date Title
WO2009081368A3 (en) Cosmetic use desmoglein i-type proteins
WO2009001260A3 (en) Cosmetic use of apolipoprotein d type proteins
WO2009081374A3 (en) Cosmetic use of plakoglobin-type proteins
ATE417595T1 (en) KERATIN-BINDING POLYPEPTIDES
WO2008068422A3 (en) Cosmetic use of a protein belonging to the ribonuclease family<0}
WO2006121610A3 (en) Personal care compositions and methods for their use
WO2008057463A3 (en) Peptide-based conditioners
WO2007064917A3 (en) Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
BRPI1010880A2 (en) growth hormone polypeptides and methods of making and using them.
WO2008142164A3 (en) Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
WO2011036442A3 (en) Thrombin c- terminal polypeptides and uses thereof for treating inflammation coagulation disorders
WO2009147248A3 (en) Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
NZ603570A (en) Biological materials related to her3
BR112012006501A8 (en) POLYPEPTIDES AND USES THEREOF
WO2005121331A3 (en) Truncated galnact2 polypeptides and nucleic acids
WO2005121332A3 (en) Truncated st6galnaci polypeptides and nucleic acids
BR112013003522A2 (en) "modified relaxin polypeptides comprising a non-naturally encoded amino acid, use, method of preparation as well as nucleic acid encoding them"
ATE454403T1 (en) HUMAN COAGULATION FACTOR VII POLYPEPTIDES
WO2012125973A3 (en) Potent and selective inhibitors of nav1.3 and nav1.7
WO2010061377A3 (en) Tissue adhesive
WO2011063320A3 (en) Recombinant filaggrin polypeptides for cell importation
EP4349361A3 (en) Peptide exhibiting wrinkle-improving activity and uses thereof
WO2007100874A3 (en) Compositions containing peptides with non-natural amino acids and methods of use
BR112013014575A2 (en) in vitro or ex vivo use, cosmetic use, process, cosmetic process, isolated peptide, in vitro or ex vivo multicellular skin composition and model
WO2011051916A3 (en) Stabilized protein formulations and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08863446

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08863446

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载